Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exosome therapy in adults with COVID-19-related ARDS
IRCT20201202049568N3Phase 2Completed
- Sponsor
- Tarmim Ava Baran
- Start
- Mar 2021
- Modality
- Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, triple-blind trial of umbilical cord derived mesenchymal stem cells exosomes in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tarmim Ava Baran. Primary endpoints: Adverse reaction and severe adverse reaction and Time to clinical improvement. Started Mar 2021; status: completed.
02
Drugs
umbilical cord derived mesenchymal stem cells exosomes
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20201202049568N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201202049568N3.